A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- A phase Ib_II study of HER3-targeting
Final published version, 749 KB, PDF document
Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC). HER3 ligand heregulin and HER3 protein expression were evaluated as potential biomarkers of clinical activity. Patients and methods This open-label, phase Ib/II study enrolled patients receiving lumretuzumab at 800 mg (flat) in combination with carboplatin (area under the curve (AUC) 6 mg/mL×min) and paclitaxel (200 mg/m 2) administered intravenously on a every 3-week schedule. Adverse event (AE) rates and tumour responses were determined. Heregulin messenger RNA (mRNA) and HER3 protein expression were investigated in archival tumour biopsies. Results Altogether, 12 patients received lumretuzumab in combination with carboplatin and paclitaxel. The most frequent AEs were gastrointestinal, haematological and nervous system toxicities, which were generally mild and manageable. Partial responses were observed in 3 of 12 patients lasting 81, 177 and 207 days. All responses were achieved in tumours expressing higher heregulin mRNA levels. Conclusion Lumretuzumab in combination with carboplatin and paclitaxel was well tolerated. Objective responses were enriched in tumours expressing higher heregulin mRNA levels.
Original language | English |
---|---|
Article number | e000532 |
Journal | ESMO Open |
Volume | 4 |
Issue number | 4 |
Number of pages | 7 |
ISSN | 2059-7029 |
DOIs | |
Publication status | Published - 2019 |
- biomarker, ErbB3, heregulin, human epidermal growth factor receptor 3 (HER3), non-small cell lung cancer (NSCLC), phase i, squamous
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 240787436